drugset / Trial / NCT04056975
Study of A-319 in Patients With Relapsed or Refractory B-cell Lymphoma
Phase 1
Unknown
54 enrolled
EVIVE Biotechnology
Peking University Cancer Hospital & Institute · collab
NaSingle-groupOpen-labelTreatment
Summary
Title: A Phase I, Single Centre, Open-label, Dose-escalation Study of A-319 in Patients With Relapsed or Refractory B-cell Lymphoma
Timeline
- Start
- 2019-09-15
- Primary completion
- 2021-09-30
- Completion
- 2022-01-27
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | A-319 | Monoclonal antibody | 0.03 ug/kg | Intravenous |
| Subject | A-319 | Monoclonal antibody | 0.05 ug/kg | Intravenous |
| Subject | A-319 | Monoclonal antibody | 0.06 ug/kg | Intravenous |
| Subject | A-319 | Monoclonal antibody | 0.12 ug/kg | Intravenous |
| Subject | A-319 | Monoclonal antibody | 0.15 ug/kg | Intravenous |
| Subject | A-319 | Monoclonal antibody | 0.18 ug/kg | Intravenous |
| Subject | A-319 | Monoclonal antibody | 0.24 ug/kg | Intravenous |